PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRituximab
Rituxan, Mabthera(rituximab)
MabThera, Riabni, Rituxan, Ruxience, Truxima (rituximab) is an antibody pharmaceutical. Rituximab was first approved as Rituxan on 1997-11-26. It is used to treat b-cell lymphoma, granulomatosis with polyangiitis, lymphoid leukemia, mantle-cell lymphoma, and microscopic polyangiitis amongst others in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia, microscopic polyangiitis, non-hodgkin lymphoma, pemphigus, and rheumatoid arthritis amongst others. The pharmaceutical is active against B-lymphocyte antigen CD20.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
nervous system diseasesD009422
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Riabni, Rituxan, Ruxience, Truxima
Combinations
Rituxan hycela
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Rituximab
Tradename
Proper name
Company
Number
Date
Products
RituxanrituximabGenentechN-103705 RX1997-11-26
2 products
Show 1 discontinued
Hyaluronidase human
+
Rituximab
Tradename
Proper name
Company
Number
Date
Products
Rituxan Hycelarituximab and hyaluronidase humanGenentechN-761064 RX2017-06-22
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
rituxan hycelaBiologic Licensing Application2021-06-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
b-cell lymphoma—D016393—
granulomatosis with polyangiitisEFO_0005297D014890M31.3
lymphoid leukemia—D007945C91
mantle-cell lymphoma—D020522C83.1
microscopic polyangiitisEFO_1000784D055953M31.7
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
Expiration
Code
rituximab, Rituxan, Genentech, Inc.
2026-09-27Orphan excl.
rituximab / hyaluronidase human, Rituxan Hycela, Genentech, Inc.
2024-06-22Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XC: Monoclonal antibodies, antineoplastic
— L01XC02: Rituximab
HCPCS
Code
Description
J9311
Injection, rituximab 10 mg and hyaluronidase
J9312
Injection, rituximab, 10 mg
Q5115
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
Q5119
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
Q5123
Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
Clinical
Clinical Trials
2477 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large b-cell lymphoma diffuseD016403—C83.310021164422347
Non-hodgkin lymphomaD008228—C85.911119152922334
B-cell chronic lymphocytic leukemiaD015451—C91.18513338423249
Follicular lymphomaD008224—C826610746112199
Mantle-cell lymphomaD020522—C83.1541071914158
Rheumatoid arthritisD001172EFO_0000685M06.91319322133113
B-cell lymphomaD016393——384761380
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0245265177
Waldenstrom macroglobulinemiaD008258HP_0005508C88.0275451172
Burkitt lymphomaD002051—C83.7203612149
Show 35 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.98420834—31320
LeukemiaD007938—C9526696—495
Hodgkin diseaseD006689—C8122375—250
B-cell lymphoma marginal zoneD018442—C88.420332—147
Myelodysplastic syndromesD009190—D469182—327
Myeloid leukemia acuteD015470—C92.09153——24
Graft vs host diseaseD006086—D89.813121—216
Large-cell lymphoma immunoblasticD016400——7101——14
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—1121——13
Chronic kidney failureD007676EFO_0003884N18.6451—311
Show 40 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C801516——123
Multiple myelomaD009101—C90.01411——120
Hairy cell leukemiaD007943—C91.4711——115
Lymphomatoid granulomatosisD008230—C83.8812———15
Hematologic neoplasmsD019337——86——114
Intraocular lymphomaD064090——89———13
Plasma cell neoplasmsD054219——46———10
Biphenotypic leukemia acuteD015456—C95.046———9
Prolymphocytic leukemiaD015463——44———8
Aids-related lymphomaD016483EFO_1001365—16———7
Show 145 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Precursor t-cell lymphoblastic leukemia-lymphomaD054218——3————3
Psoriatic arthritisD015535EFO_0003778L40.51———23
Mycosis fungoidesD009182—C84.01————1
DiseaseD004194EFO_0000408R691————1
Immunoglobulin g4-related diseaseD000077733—D89.841————1
Bone marrow transplantationD016026——1————1
Wiskott-aldrich syndromeD014923EFO_0003903D82.01————1
Treatment-resistant schizophreniaD000090663——1————1
Eyelid diseasesD005141EFO_0009547H02.91————1
Macular degenerationD008268EFO_0001365H35.301————1
Show 6 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SpondylarthritisD025241——————22
Hemoglobin sc diseaseD006450EFO_1001797D57.2————11
DepressionD003863—F33.9————11
AnxietyD001007EFO_0005230F41.1————11
Juvenile arthritisD001171EFO_1002007M08————11
UveitisD014605HP_0000554H20.9————11
Acquired immunodeficiency syndromeD000163EFO_0000765B20————11
Liver diseasesD008107HP_0002910K70-K77————11
Pathologic processesD010335——————11
Drug hypersensitivityD004342EFO_0009482T88.7————11
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRituximab
INNrituximab
Description
Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow injection into a vein.
Classification
Antibody
Drug classmonoclonal antibodies: chimeric, tumors as target
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>1L6X:A|IMMUNOGLOBULIN GAMMA-1 HEAVY CHAIN CONSTANT REGION GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL >1L6X:B|Minimized B-domain of Protein A Z34C FNMQCQRRFYEALHDPNLNEEQRNAKIKSIRDDC
Identifiers
PDB1L6X, 2OSL, 4KAQ, 6VJA, 6Y90
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201576
ChEBI ID—
PubChem CID—
DrugBankDB00073
UNII ID4F4X42SYQ6 (ChemIDplus, GSRS)
Target
Agency Approved
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
MS4A1
Gene synonyms
CD20
NCBI Gene ID
931
Protein name
B-lymphocyte antigen CD20
Protein synonyms
B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, CD20, CD20 antigen, CD20 receptor, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1
Uniprot ID
Q13963
Mouse ortholog
Ms4a1 (12482)
B-lymphocyte antigen CD20 (P19437)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Rituxan – Biogen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Rituxan – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Ruxience – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Rituximab
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 75,350 documents
View more details
Safety
Black-box Warning
Black-box warning for: Rituxan hycela
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
138,528 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use